ArticleJournal of applied toxicology : JAT2026
Synthesis and Characterization of Juglone-Derived cu (II), Mn (II) and Zn (II) Complexes and Investigation of Their Cytotoxic Activities Against Lung and Colon Cancer Cells in Vitro and in Silico.
Article in Journal of applied toxicology : JAT, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Three new Zn (II), Cu (II) and Mn (II) complexes have been synthesized from 5-hydroxy-1,4-naphthoquinone (HNQ). Elemental analysis, magnetic susceptibility, UV-Vis, IR and Mass spectrometry have all been used to explore the structural characterization of these compounds. When the electronic spectra of these compounds are examined, they correspond to π → π* transitions in the 261-262 nm range, n → π* transitions in the 316-354 nm range, and charge transfer transitions in the 417-423 nm range. Also, in vitro cytotoxic activities of both juglone ligand and its metal complexes against A549 lung cancer and HT-29 colon cancer cells have been investigated. The Mn (II)-Juglone complex showed better cytotoxic activity than juglone ligand and other metal complexes in both cell lines. Moreover, molecular docking analyses demonstrated that the Mn (II)-Juglone complex exhibited stronger binding interactions with both DNA and the anti-apoptotic protein Bcl-2 compared to the free Juglone ligand. Annexin V/PI double staining results using flow cytometry showed that there were more total apoptotic cells in the Mn (II)-Juglone complex-treated groups than in the ligand-treated groups in both cell lines. In addition, it was found that Cas-3 and Bax immunoreactivity increased significantly and Bcl-2 immunoreactivity decreased significantly in Mn (II)-Juglone complex-treated groups compared to the control and ligand groups.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.